Abstract
Vaccines, as biological methods used in healthcare, preceded the development of modern biotechnology. These can now be covered under the theme of this book as many biotechnologies are applied to refining and manufacturing vaccines. Vaccines have probably prevented more diseases than any other medical or public health intervention except sanitation. The traditional use of vaccines has been mostly limited to the prevention of disease. The trend changed in the 1990s when several clinical trials were underway for treatment of active infections with viruses such as HIV-1 and the herpes simplex virus. DNA vaccines, which are easy to produce and stable, were the most important development in this area in the last decade. A brief review of history of vaccination is given as a part of introduction.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ang BT, Xu G, Xiao ZC. Therapeutic vaccination for central nervous system repair. Clin Exp Pharmacol Physiol 2006;33:541–5.
Appaiahgari MB, Vrati S. IMOJEV(®): a Yellow fever virus-based novel Japanese encephalitis vaccine. Expert Rev Vaccines 2010;9:1371–84.
Bevins RA, Wilkinson JL, Sanderson SD. Vaccines to combat smoking. Expert Opin Biol Ther 2008;8:379–83.
Calmette A. La vaccination prevente contra la tuberculose par le BCG. Masson, Paris, France 1927.
Cyrus SS; Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention. Protecting the world against meningitis: new recommendations from the CDC’s advisory committee on immunization practices. J Am Osteopath Assoc 2011;111(10 Suppl 6):S17-9.
Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer’s disease. Brain Pathol 2004;14:11–20.
Gilden D. Efficacy of live zoster vaccine in preventing zoster and postherpetic neuralgia. J Intern Med 2011;269:496–506.
Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 2006;103:10834–9.
Hawkes CA, McLaurin J. Immunotherapy as treatment for Alzheimer’s disease. Expert Rev Neurother 2007;7:1535–48.
Ishikawa E, Tsuboi K, Yamamoto T, et al. Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients. Cancer Sci 2007;98:1226–33.
Jain KK. Drug-induced neurological disorders. 3rd ed. Gottingen-Seattle: Hogrefe & Huber, 2012.
Jenner E. An inquiry into the causes and effects of variolae vacciniae, a disease discovered in some western counties of England, particularly Gloucestershire, and known by the name of cow pox. London, 1798. Reprinted in: Camac CN, editor. Classics of Medicine and Surgery. Diver: New York, 1959:213–40.
Jones T. IC-51, an injectable vaccine for the prevention of Japanese encephalitis virus infection. Curr Opin Mol Ther 2009;11:90–6.
Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 2010;6:108–19.
Liang XF, Li L, Liu DW, et al. Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China. N Engl J Med 2011;364:638–47.
Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 2005;11:5515–25.
Lindsey NP, Staples JE, Jones JF, et al. Adverse event reports following Japanese encephalitis vaccination in the United States, 1999–2009. Vaccine 2010;29:58–64.
Loftus B, Newsom B, Montgomery M, et al. Autologous attenuated T-cell vaccine (Tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies. Clin Immunol 2009;131:202–15.
Martell BA, Mitchell E, Poling J, Gonsai K, Kosten TR. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 2005;58:158–64.
Miller L, Reynolds J. Autism and vaccination-the current evidence. J Spec Pediatr Nurs 2009;14:166–72.
Okura Y, Matsumoto Y. Development of anti-Abeta vaccination as a promising therapy for Alzheimer’s disease. Drug News Perspect 2007;20:379–86.
Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271–84.
Pass RF, Zhang C, Evans A, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 2009;360:1191–9.
Pasteur L, Chamberland CE, Roux E. Sur la vaccination charbonneuse. CR Acad Sci Paris 1881;95:1250–2.
Perriol MP, Devos D, Hurtevent JF, Gautier S, Caron J, Destee A. Flaccid tetraplegia following anti-tetanus vaccination. Rev Neurol (Paris) 2004;160:942–4.
Poland GA. Vaccines against Lyme disease: What happened and what lessons can we learn? Clin Infect Dis 2011;52 Suppl 3:s253-8.
Qu B, Boyer PJ, Johnston SA, Hynan LS, Rosenberg RN. Abeta42 gene vaccination reduces brain amyloid plaque burden in transgenic mice. J Neurol Sci 2006;244(1–2):151–8.
Rivera VM. Tovaxin for multiple sclerosis. Expert Opin Biol Ther 2011;11:961–7.
Rutschmann OT, McCrory DC, Matchar DB. Immunization and MS: a summary of published evidence and recommendations. Neurology 2002;59:1837–43.
Sabin AB. Oral poliovirus vaccine: history of its developments and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis 1985;151:420–36.
Salk JE. Considerations in the preparation and use of poliomyelitis virus vaccine. JAMA 1955;158:1239–48.
Schwartz M, Kipnis J. Therapeutic T cell-based vaccination for neurodegenerative disorders: The role of CD4 + CD25+ regulatory T cells. Ann N Y Acad Sci 2005;1051:701–8.
Shen XY, Orson FM, Kosten TR. Vaccines against drug abuse. Clin Pharmacol Ther 2012;91:60–70.
Simberkoff MS, Arbeit RD, Johnson GR, et al.; Shingles Prevention Study Group. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med 2010;152:545–54.
Smith MJ. Meningococcal tetravalent conjugate vaccine. Expert Opin Biol Ther 2008;8:1941–6.
Snape MD, Perrett KP, Ford KJ, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 2008;299:173–84.
Snape MD, Pollard AJ. Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect Dis 2005;5:21–30.
Sonabend AM, Dana K, Lesniak MS. Targeting epidermal growth factor receptor variant III: a novel strategy for the therapy of malignant glioma. Expert Rev Anticancer Ther 2007;7(12 Suppl):S45-50.
Tseng HF, Liu A, Sy L, et al. Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study. J Intern Med 2012;271:510–20.
Tullu MS, Rodrigues S, Muranjan MN, Bavdekar SB, Kamat JR, Hira PR. Neurological complications of rabies vaccines. Indian Pediatr 2003;40:150–4.
Urushitani M, Ezzi SA, Julien JP. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2007;104:2495–500.
Weinberg A, Zhang JH, Oxman MN, et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis 2009;200:1068–77.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Jain, K.K. (2013). Vaccines for Neurological Disorders. In: Applications of Biotechnology in Neurology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-272-8_14
Download citation
DOI: https://doi.org/10.1007/978-1-62703-272-8_14
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-271-1
Online ISBN: 978-1-62703-272-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)